enfortumab vedotin
astellas,cleveland clinic,seagen
['vedo', 'unite study', 'brca', ' vedo', '#unite', 'urothelial', 'urothelial carcinoma', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'blcsm', 'biomarker', ' uc,(-ucsd),(-ucsf),', 'cleveland ', 'marker ']
rapid abstract session #gu23 #blcsm biomarker of response to #ev in patients with advanced urothelial carcinoma: analysis of the #unite study. 
Oncólogo Clínico staff @IAF_Fleming. Miembro @SelnetH2020 @aaoncoclinica. Interesado en #GUcsm. #clinicaltrials. #Immunotherapy #PrecisionMedicine #oncoalert